Success Story: NIW Approved in Just 19 Days! Chinese Research Scientist Achieves Rapid Success
Client’s Testimonial:
“Trust NAILG.”
On March 26th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the Field of Immunotherapy (Approval Notice).
General Field: Immunotherapy
Position at the Time of Case Filing: Research Scientist
Country of Origin: China
State of Residence at the time of filing: Florida
Approval Notice Date: March 26th, 2025
Processing Time: 19 days (Premium Processing Requested)
Case Summary:
We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to an immunotherapy researcher from China whose work is helping advance cancer treatment by developing next-generation immunotherapies. At the time of filing, the client was employed as a research scientist and had already produced impactful work in the field of immunotherapy, particularly in the treatment of solid tumors resistant to existing therapies.
Research with Substantial Merit and National Importance:
After thoroughly reviewing the client’s academic and research accomplishments, NAILG determined that the client’s work addressed critical gaps in the treatment of solid tumors. The client’s proposed endeavor, to develop next-generation immunotherapies, has the potential to revolutionize immunotherapy by overcoming therapy resistance and improving outcomes for patients with difficult-to-treat cancers. His innovative research contributes to advancing biotechnologies, genome engineering, and viral delivery systems, areas officially recognized as critical and emerging technologies in the United States. His work addresses major national healthcare concerns and supports economic growth through innovations in cancer therapy.
Well Positioned to Advance the Proposed Endeavor:
NAILG demonstrated that the client is exceptionally well-positioned to continue his proposed research in the U.S. The client holds a Ph.D. in biological sciences and has served in various advanced research roles. At the time of filing, he was employed at a leading cancer research institute where he was actively engaged in work aligned with his proposed endeavor. He has published 12 peer-reviewed journal articles, 4 first-authored conference abstracts, and 1 first-authored preprint. He is also the inventor of a granted patent. His work has accumulated 568 citations according to Google Scholar, and at least three of his publications rank among the most highly cited in the field of immunology for their years of publication. These citation records confirm the originality and continued impact of his contributions.
Further strengthening his credentials, the client has performed at least 25 expert peer reviews, a recognition of his professional standing and authority in the field. He has also secured funding from highly respected institutions, which invest in projects with significant clinical and societal relevance.
Supporting Testimonials:
To further validate the national importance and impact of the client’s work, NAILG included two letters of recommendation from leading experts in immunotherapy. These letters confirmed that the client’s research is pivotal in developing effective therapies for treatment-resistant tumors and that his work continues to shape the direction of cancer immunotherapy research.
Final Result:
Thanks to the compelling and well-documented petition prepared by the attorneys at NAILG, USCIS approved the client’s EB-2 NIW petition in just 19 days under premium processing. We are proud to have supported this researcher in securing a successful outcome and are confident that his continuing work will contribute meaningfully to public health and technological progress in the United States.